Lukas Hainz

Lukas Hainz

Biopharma Innovation Specialist
Lukas Hainz specializes in biopharmaceutical research and development. He unpacks research from clinical trials and explores regulatory affairs implications on the pharmaceutical industry, focusing on innovative therapies and patent development.
AI Platform to Revive Shelved Rare Disease Therapies
Research & Development AI Platform to Revive Shelved Rare Disease Therapies

A groundbreaking collaboration is set to address a critical paradox in modern medicine, where potentially life-saving therapies for ultra-rare diseases are abandoned not for lack of scientific merit, but due to insufficient commercial appeal. The American Society of Gene & Cell Therapy (ASGCT) and

AI-Powered Chart Review – Review
Tech & Innovation AI-Powered Chart Review – Review

In the digital age of medicine, clinicians are paradoxically drowning in an ocean of patient data while simultaneously thirsting for clear, actionable insights at the point of care. The emergence of AI-Powered Chart Review represents a significant advancement in the healthcare technology sector,

Are We Winning the Fight Against Cervical Cancer?
Research & Development Are We Winning the Fight Against Cervical Cancer?

Today we are speaking with Ivan Kairatov, a biopharma expert whose work at the intersection of public health and cancer epidemiology sheds light on one of the world’s most preventable cancers. We’ll be exploring the complex story behind cervical cancer: a disease for which we have the tools to

Nuclera’s Tech Powers Taiwan's New Drug Discovery Hub
Tech & Innovation Nuclera’s Tech Powers Taiwan's New Drug Discovery Hub

We are joined today by Ivan Kairatov, a biopharma expert with deep insights into the technological innovations shaping the future of medicine. We will be exploring the recent expansion of a groundbreaking protein discovery platform into Asia, discussing its installation at two leading Taiwanese

Next-Gen Liquid Biopsy vs. Current Assays: A Comparative Analysis
Research & Development Next-Gen Liquid Biopsy vs. Current Assays: A Comparative Analysis

The ability to track cancer's genetic secrets through a simple blood draw is no longer a futuristic concept but a clinical reality facing its own set of critical challenges. For years, the field of oncology has been steadily moving away from invasive tissue biopsies toward liquid biopsies, a

Why Are States Rewriting America's Health Rules?
Research & Development Why Are States Rewriting America's Health Rules?

A conservative West Virginia lawmaker and a progressive California governor rarely find common ground, yet they have become improbable allies in a sweeping national movement to fundamentally reshape what Americans eat and how public health is managed. This decentralized but powerful crusade,

New Hope for Parkinson's as Two Therapies Near Approval
Research & Development New Hope for Parkinson's as Two Therapies Near Approval

For the millions of people living with the relentless progression of Parkinson's disease, the daily battle for motor control has long been fought with a limited and often burdensome arsenal of treatments. The landscape of this fight is on the cusp of a dramatic transformation, however, as two

Could Robotic Trousers Be Astronauts' New Space Legs?
Tech & Innovation Could Robotic Trousers Be Astronauts' New Space Legs?

The dream of long-duration missions to the Moon and Mars carries with it a harsh physiological reality: the human body, evolved for Earth's gravity, deteriorates alarmingly in space. Prolonged exposure to microgravity triggers a cascade of deconditioning effects, including severe muscle atrophy,

Can a Polyp Test Reveal Hidden Cancer Risk?
Research & Development Can a Polyp Test Reveal Hidden Cancer Risk?

A recent international study is fundamentally changing the way clinicians understand and diagnose hereditary colorectal cancer, revealing that a direct analysis of colorectal polyp DNA can uncover critical information that standard blood tests frequently overlook. This groundbreaking research, a

Resilience Is the New Biopharma Blockbuster
Editorial Resilience Is the New Biopharma Blockbuster

The biopharmaceutical sector is entering a new era. After last year's market disruptions, the industry faces a harsh truth: scientific breakthroughs alone are no longer enough to keep ahead of the competition, maintain investor confidence, and position for a brighter future. The defining challenge

Loading
Latest Articles

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later